|Mr. Michael A. Sherman||CEO, Pres & Director||869.4k||N/A||1966|
|Mr. Michael T. Andriole M.B.A.||Chief Bus. Officer, Sec. & CFO||539.79k||N/A||1973|
|Dr. Michael A. Alrutz||Sr. VP, Gen. Counsel & Corp. Sec.||619.5k||N/A||1970|
|Mr. David Jakeman||Exec. Director of Fin. & Accounting and Principal Accounting Officer||N/A||N/A||1977|
|Dr. Roy W. Ware Ph.D., MBA||Chief Manufacturing & Technology Officer||N/A||N/A||N/A|
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Chimerix, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 7. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 9.